Employers have recently seen a significant increase in healthcare spend within the metabolic/weight loss management category due to the promotion of new “diet drugs” such as Wegovy, Ozempic and Mounjaro. With over 142 million adults nationwide meeting the criteria for these medical treatments, employers and plan sponsors need to understand their impact on employee benefit plans.
Register now to learn more about these treatments and how to properly manage their utilization. This webinar will provide you with:
Don’t miss out on this informative webinar! Click here to register!
